author-photo

Eckart Laack

University of Hamburg

80

Papers

3280

Citations

Citation Trend

Filter By

Papers (80) Sort By

JournalConferenceOthers

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

2021 Therapeutic Advances in Medical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.

2021 Therapeutic Advances in Medical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV.

2021 Translational lung cancer research
Show All
- Source
- Cite
- Save
Citations (2)
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice:

2021 Therapeutic Advances in Medical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non–small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)
Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small- cell lung cancer (NSCLC) : results from cohort 6 of the phase 2 GEOMETRY mono-1 study

2020 Onkologie
Show All
- Source
- Cite
- Save
Citations (0)
Biomarker testing in non-small cell lung cancer in routine care: analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

2020 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (9)
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer

2020 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (140)
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.

2020 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (49)
CheckMate 384 : essai clinique de phase 3b/4 évaluant nivolumab 480 mg toutes les 4 semaines (Q4S) vs nivolumab 240 mg toutes les 2 semaines (Q2S) chez les patients (pts) atteints d’un cancer bronchique non à petites cellules (CBNPC) avancé préalablement traité par nivolumab pendant une durée ≤ 12 mois

2020 Revue des Maladies Respiratoires Actualités
Show All
- Source
- Cite
- Save
Citations (0)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号